Tvardi Therapeutics Q2 net loss slightly lower estimates

Tvardi Therapeutics

14/08/2026 12:08

Overview
US biopharma firm's Q2 net loss was $6.5 mln, a slight beat versus analyst expectations
Research and development expenses fell due to lower clinical costs for TTI-101

Outlook
Company expects existing cash to fund operations through HCC topline readout into Q3 2027
Initiation of TTI-109 UC clinical trial planned for 2027, subject to IND clearance and funding
Advancing TTI-109 into UC and other indications will require additional funding and IND clearance

Result Drivers
TTI-109 DEVELOPMENT - Co said Q2 results reflected increased development costs for next-generation STAT3 inhibitor TTI-109, partially offsetting lower clinical costs for TTI-101

Company press release: ID:nGNX4VBrgH

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.69
 
Q2 Net Loss
Slight Beat*
$6.50 mln
$6.54 mln (8 Analysts)
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Tvardi Therapeutics, Inc. is $9.50, about 436.7% above its August 13 closing price of $1.77

Reuters Recommended Reads
Aug 14 - Rein Therapeutics Q2 net loss narrows on lower R&D spending
Aug 13 - Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Aug 13 - Celcuity posts narrower-than-expected loss as R&D costs decreased

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)